贝那利珠单抗治疗伴新型STAT3功能缺失突变的泼尼松依赖性嗜酸性哮喘
本文报告一例58岁女性泼尼松依赖性哮喘患者,表现为混合性嗜酸性及中性粒细胞性支气管炎反复急性加重。基因检测发现新型致病性STAT3突变,诊断为常染色体显性高IgE综合征。该IL-5驱动的嗜酸粒细胞增多经抗IL-5生物制剂贝那利珠单抗治疗成功。
要点
- 泼尼松依赖性哮喘反复加重需警惕原发性免疫缺陷可能。
- STAT3功能缺失突变可表现为高IgE综合征伴嗜酸粒细胞增多。
- 抗IL-5生物制剂可用于STAT3突变相关IL-5驱动嗜酸粒细胞增多。
核心结论
- 伴新型STAT3功能缺失突变的泼尼松依赖性嗜酸性哮喘,经抗IL-5生物制剂贝那利珠单抗治疗成功。
研究设计与样本
- 单个病例报告,58岁女性,泼尼松依赖性哮喘伴混合性嗜酸性及中性粒细胞性支气管炎反复急性加重。
主要发现
- 患者存在混合性嗜酸性及中性粒细胞性支气管炎,反复急性加重。
- 基因检测发现新型致病性STAT3突变,诊断为常染色体显性高IgE综合征。
- 该嗜酸粒细胞增多为IL-5驱动,经贝那利珠单抗治疗成功。
临床怎么用
- 对泼尼松依赖性哮喘反复加重患者,应考虑评估原发性免疫缺陷如STAT3突变。
- STAT3突变相关IL-5驱动嗜酸粒细胞增多可尝试抗IL-5生物制剂治疗。
局限性
- 为单例病例报告,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Some severe asthmatic patients experience frequent bacterial respiratory tract infections, which contribute significantly to their disease burden, and often are attributed to their use of systemic corticosteroids and comorbid bronchiectasis. We report a case of a 58-year-old woman who had prednisone-dependent asthma and exacerbations with intense mixed eosinophilic and neutrophilic bronchitis. Autosomal dominant hyper-IgE syndrome, which is a primary immunodeficiency characterized by elevated IgE, eosinophilia, and recurrent infections, caused by a novel pathogenic mutation in STAT3 was identified as the cause of her airway disease. We believe that this is the first report of the demonstration of an IL-5 driven eosinophilia that is associated with a STAT3 mutation that was treated successfully with an anti-IL5 biological.
引用
- Adatia A, Allen CJ, Wald J, et al. Benralizumab for Prednisone-Dependent Eosinophilic Asthma Associated With Novel STAT3 Loss of Function Mutation. Chest. 2021. PMID: 34022014. doi:10.1016/j.chest.2020.11.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。